A possible explanation of failure of the CPS + EG and the Neo-Bioscore prediction is that the characteristics of breast cancer cases in China (e.g. age and menopausal status) and the HER2-positive patients without trastuzumab therapy compromised the extent of survival stratification (34). This evidence concerns the gene ERBB2 and breast cancer.